looking at peers such as 4DX ($600 mil ) and EMV ( $220 mil) . One has FDA approval but no contracts yet. Other one is in phase 1 trials . Nico with 8-15 hospitals in Europe and FDA / CE/ TGA approvals should be worth north of a minimum of $100 mil. Nearest peer to benchmark in AI stroke care is Viz AI. They got their FDA approval in 2018/2018 and post that they were able to get into the US rebate program for stroke diagnostics , similar to Nico. That company by my rough calcs is easily worth around $800 mil. blue sky from here . Lots of catalysts over next 12 months .
